Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

Stock Information for Gain Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gain Therapeutics Inc.

Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.